한글목차

세계 황반변성(AMD) 및 기타 망막질환 치료제 시장 규모는 2033년까지 7.4%의 CAGR을 나타낼 것으로 예상됩니다.

망막질환 발생률 증가와 노령인구 증가가 산업 성장 견인

시장 성장은 여러 가지 중요한 요인에 의해 주도되고 있습니다. 주요 요인은 망막 질환, 특히 AMD의 발생이 증가하고 있다는 점입니다. 이러한 질환의 유병률은 세계적으로 증가하고 있으며, 고령화, 건강에 해로운 생활습관, 흡연 및 장시간의 스크린 사용과 같은 위험 요소에 대한 노출 증가가 그 원인으로 꼽힙니다. AMD는 노년층 시력 저하의 주요 원인인 AMD는 안과 분야에서 주목받고 있으며, R&D 및 혁신적 치료법에 대한 투자가 증가하고 있습니다.

또한, 노인 인구 증가도 시장 성장에 큰 기여를 하고 있습니다. 고령화가 진행됨에 따라 AMD와 같은 망막 질환에 걸릴 확률이 높아집니다. 세계적으로 노인 인구의 비율이 증가함에 따라 이러한 질환을 관리하고 시력을 유지할 수 있는 효과적인 치료법에 대한 수요가 증가하고 있습니다. 이러한 인구 통계학적 변화는 첨단 치료제와 종합적인 관리 전략의 필요성을 강조하며, AMD 및 기타 망막 질환 치료제 시장을 주도하고 있습니다.

AMD에 대한 인식 부족이 시장 성장의 걸림돌로 작용할 가능성

한편, 이 시장은 AMD에 대한 인식 부족이라는 큰 문제에 직면해 있습니다. 이는 시력 장애와 시력 상실을 초래하는 진행성 안과 질환인 AMD에 대한 일반인과 의료 전문가 모두에 대한 이해와 지식이 제한적이기 때문입니다.

세계 황반변성(AMD) 및 기타 망막질환 치료제 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 요인 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter의 Five Forces 분석
• PEST 분석

제4장 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석 : 적응증별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산·예측
• AMD
• 당뇨병성 황반부종
• 당뇨병성 망막증
• 망막 정맥 폐쇄
• 기타

제5장 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석 : 투여 경로별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산·예측
• 유리체내
• 정맥

제6장 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석 : 유통 채널별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추산·예측
• 병원 약국
• 소매 약국
• E-Commerce 약국

제7장 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석 : 브랜드별

• 주요 조사 결과
• 시장 규모 추산·예측

제8장 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추산·예측

제9장 북미의 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석

제10장 유럽의 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석

제11장 아시아태평양의 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석

제12장 라틴아메리카의 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석

제13장 중동 및 아프리카의 황반변성(AMD) 및 기타 망막 질환 치료제 시장 분석

제14장 기업 개요

• 경쟁 구도
• 전략적 전망
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Bausch &Lomb Incorporated
• Santen Pharmaceutical Co., Ltd.
• Johnson &Johnson Services, Inc.
• Regeneron Pharmaceuticals Inc.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Apellis Pharmaceuticals
• Alimera Sciences
• EyeBio
• SpliceBio
• Breye Therapeutics ApS

제15장 결론 및 제안

• Visiongain의 결론
• 시장 진출기업에 대한 제안

영문목차

The global Macular Degeneration (AMD) and Other Retinal Diseases Drugs market is projected to grow at a CAGR of 7.4% by 2033.

“The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise in Incidence of Retinal Disorders and Upsurge in Geriatric Population Driving Industry Growth

The growth of the market for Macular Degeneration (AMD) and Other Retinal Diseases is significantly driven by various important factors. A primary contributor is the increasing occurrence of retinal conditions, particularly macular degeneration. The prevalence of these ailments is on the upswing globally, attributed to factors such as the aging population, unhealthy lifestyles, and increased exposure to risk elements like smoking and extended screen usage. Macular degeneration, a primary cause of vision loss in older individuals, has gained notable attention in the field of ophthalmology, resulting in increased investments in research, development, and innovative treatment methods.

Furthermore, the rise in the elderly population significantly contributes to market growth. As people age, the likelihood of developing retinal conditions such as AMD rises. With a growing proportion of elderly individuals worldwide, there's a heightened demand for effective treatments to manage these conditions and preserve vision. This demographic shift accentuates the need for advanced therapeutics and comprehensive management strategies, driving the market for drugs and treatments targeting AMD and other retinal diseases.

In summary, the combination of a growing occurrence of retinal disorders and an expanding elderly population underscores the substantial demand for advancements in the Macular Degeneration (AMD) and Other Retinal Diseases Market. This highlights the importance of ongoing research, innovation, and accessible treatments to meet the evolving healthcare requirements of aging populations.

Lack of Awareness Regarding AMD Likely to Challenge Market Growth

The market for treating Macular Degeneration (AMD) and Other Retinal Diseases is significantly impacted by a major challenge-insufficient awareness regarding AMD. This predicament stems from a limited comprehension and knowledge within both the general populace and healthcare professionals about AMD, a progressive eye ailment that can result in vision impairment or loss. The issue centres around the fact that numerous individuals, particularly those in vulnerable demographics, lack awareness about the risk factors, symptoms, and potential consequences associated with AMD.

This deficiency in awareness creates notable obstacles for early diagnosis and timely intervention, as affected individuals may fail to identify the indicators of AMD until it reaches an advanced stage, diminishing the effectiveness of treatment options. Moreover, healthcare providers may face difficulty in detecting AMD during its initial phases due to the absence of routine screenings and inadequate public education about the condition.

What Questions Should You Ask before Buying a Market Research Report?

• How is the macular degeneration (AMD) and other retinal diseases drugs market evolving?
• What is driving and restraining the macular degeneration (AMD) and other retinal diseases drugs market?
• How will each macular degeneration (AMD) and other retinal diseases drugs market segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each macular degeneration (AMD) and other retinal diseases drugs market submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading macular degeneration (AMD) and other retinal diseases drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of macular degeneration (AMD) and other retinal diseases drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the macular degeneration (AMD) and other retinal diseases drugs market?
• Where is the macular degeneration (AMD) and other retinal diseases drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market today, and over the next 10 years:

• Our 284-page report provides 115 tables, 151 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising drug development prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Disease Indication

• AMD

Wet AMD

Dry AMD

• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Others

Route of Administration

• Parenteral
• Topical

Brands

• Lucentis
• Eylea
• Avastin
• Beovu
• Vabysmo
• Ozurdex
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacy
• E-commerce Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Netherlands
• Switzerland
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC Countries
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 in terms of value the market will surpass US$15.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033” report help you?

In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 Market, with forecasts for disease indication, route of administration, distribution channel, and brand each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 24 key national markets - See forecasts for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drug Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Rise in Incidence of Retinal Disorders
    • 3.2.1.2 Upsurge in Geriatric Population
    • 3.2.1.3 Rising Healthcare Expenditure by Various Governments
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Lack of Awareness Regarding AMD
    • 3.2.2.2 Side Effects of Drugs
    • 3.2.2.3 High Cost Associated with Macular Degeneration and Other Retinal Diseases
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Disorders to Aid Market
    • 3.2.3.2 Untapped Opportunities for the Dry AMD Treatment
    • 3.2.3.3 Increasing Adoption of New Technologies for Treatment
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis
  • 3.5.1 Political
  • 3.5.2 Economical
  • 3.5.3 Social
  • 3.5.4 Technological

4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Disease Indication

• 4.1 Key Findings
• 4.2 Disease Indication Segment: Market Attractiveness Index
• 4.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
• 4.4 AMD
  • 4.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.4.3 AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market
• 4.5 Diabetic Macular Edema
  • 4.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)
• 4.6 Diabetic Retinopathy
  • 4.6.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.6.2 Market Share by Region, 2023 & 2033 (%)
• 4.7 Retinal Vein Occlusion
  • 4.7.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.7.2 Market Share by Region, 2023 & 2033 (%)
• 4.8 Others
  • 4.8.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Route of Administration

• 5.1 Key Findings
• 5.2 Route of Administration Segment: Market Attractiveness Index
• 5.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of administration
• 5.4 Intravitreal Route
  • 5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Intravenous Route
  • 5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)

6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Distribution Channel

• 6.1 Key Findings
• 6.2 Distribution Channel Segment: Market Attractiveness Index
• 6.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution Channel
• 6.4 Hospital Pharmacies
  • 6.4.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Retail Pharmacy
  • 6.5.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)
• 6.6 E-Commerce Pharmacy
  • 6.6.1 Market Size by Region, 2023-2033 (US$ Billion)
  • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Brands

• 7.1 Key Findings
• 7.2 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Brands

8 Macular degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Region

• 8.1 Key Findings
• 8.3 Regional Market Size Estimation and Forecast

9 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

• 9.1 Key Findings
• 9.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
• 9.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 9.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
• 9.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
  • 9.5.1 North America AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
• 9.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
• 9.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
• 9.8 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 9.9 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

10 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

• 10.1 Key Findings
• 10.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
• 10.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 10.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
• 10.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
  • 10.5.1 Europe AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
• 10.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
• 10.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
• 10.8 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.9 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.10 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.11 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.12 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.13 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.14 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 10.15 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

11 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
• 11.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 11.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
• 11.5 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
  • 11.5.1 Asia-Pacific AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
• 11.6 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
• 11.7 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
• 11.8 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 11.9 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 11.10 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 11.11 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 11.12 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 11.13 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 11.14 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

12 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
• 12.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 12.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
• 12.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
  • 12.5.1 Latin America AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
• 12.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
• 12.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution Channel
• 12.8 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 12.9 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 12.10 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 12.11 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

13 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

• 13.1 Key Findings
• 13.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
• 13.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
• 13.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
• 13.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
  • 13.5.1 MEA AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
• 13.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
• 13.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
• 13.8 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 13.9 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
• 13.10 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2023
• 14.2 Strategic Outlook
• 14.3 Novartis AG
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2018-2022
    • 14.3.3.2 Regional Market Shares, 2022
    • 14.3.3.3 R&D Expense, 2018-2022
  • 14.3.4 Product Offered
  • 14.3.5 Strategic Outlook
• 14.4 Bayer AG
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Net Revenue, 2018-2022
    • 14.4.3.2 Regional Market Shares, 2022
    • 14.4.3.3 R&D Expense, 2018-2022
  • 14.4.4 Products Offered
  • 14.4.5 Strategic Outlook
• 14.5 Pfizer Inc.
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Revenue, 2018-2022
    • 14.5.3.2 Regional Market Shares, 2022
    • 14.5.3.3 R&D Expense, 2018-2022
  • 14.5.4 Products Offered
  • 14.5.5 Strategic Outlook
• 14.6 Bausch & Lomb Incorporated
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Revenue, 2018-2022
    • 14.6.3.2 R&D Expense, 2018-2022
  • 14.6.4 Products Offered
  • 14.6.5 Strategic Outlook
• 14.7 Santen Pharmaceutical Co., Ltd.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Revenue, 2018-2022
    • 14.7.3.2 R&D Expense, 2018-2022
  • 14.7.4 Products Offered
  • 14.7.5 Strategic Outlook
• 14.8 Johnson & Johnson Services, Inc.
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
    • 14.8.3.1 Revenue, 2018-2022
    • 14.8.3.2 Regional Market Shares, 2022
    • 14.8.3.3 R&D Expense, 2018-2022
  • 14.8.4 Products Offered
  • 14.8.5 Strategic Outlook
• 14.9 Regeneron Pharmaceuticals Inc.
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Revenue, 2018-2022
    • 14.9.3.2 R&D Expense, 2018-2022
  • 14.9.4 Products Offered
  • 14.9.5 Strategic Outlook
• 14.10 AbbVie Inc.
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Revenue, 2018-2022
    • 14.10.3.2 Regional Market Shares, 2022
    • 14.10.3.3 R&D Expense, 2018-2022
  • 14.10.4 Products Offered
  • 14.10.5 Strategic Outlook
• 14.11 F. Hoffmann-La Roche Ltd.
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Revenue, 2018-2022
    • 14.11.3.2 Regional Market Shares, 2022
  • 14.11.4 Products Offered
  • 14.11.5 Strategic Outlook
• 14.12 Teva Pharmaceutical Industries Ltd.
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Revenue, 2018-2022
    • 14.12.3.2 Regional Market Shares, 2022
    • 14.12.3.3 R&D Expense, 2018-2022
  • 14.12.4 Products Offered
  • 14.12.5 Strategic Outlook
• 14.13 Apellis Pharmaceuticals
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Revenue, 2018-2022
    • 14.13.3.2 R&D Expense, 2018-2022
  • 14.13.4 Products Offered
  • 14.13.5 Strategic Outlook
• 14.14 Alimera Sciences
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Financial Analysis
    • 14.14.3.1 Revenue, 2018-2022
    • 14.14.3.2 R&D Expense, 2018-2022
  • 14.14.4 Products Offered
  • 14.14.5 Strategic Outlook
• 14.15 EyeBio
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Products Offered
  • 14.15.4 Strategic Outlook
• 14.16 SpliceBio
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Products Offered
  • 14.16.4 Strategic Outlook
• 14.17 Breye Therapeutics ApS
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Products Offered
  • 14.17.4 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players